Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erlotinib hydrochloride.

John D Minna1, Jonathan Dowell

  • 1Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center at Dallas, 75390-8593, USA. john.minna@utsouthwestern.edu

Nature Reviews. Drug Discovery
|June 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Co-medications and gut microbiome in NSCLC immunotherapy.

The Lancet. Oncology·2026
Same author

Monoclonal antibodies targeting PCDH7 inhibit tumor growth and enhance immune responses in <i>KRAS</i>-mutant non-small cell lung cancer.

Science advances·2026
Same author

Understanding immune checkpoint inhibitor efficacy through spatial decoding of the lung cancer tumor immune microenvironment.

The Journal of clinical investigation·2026
Same author

Association of Vaping-Related Events with Relative Harm Perceptions of E-Cigarettes.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2026
Same author

Cancer cachexia in STK11/LKB1-mutated non-small cell lung cancer is dependent on tumor-secreted GDF15.

Nature communications·2026
Same author

ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin.

Molecular cancer therapeutics·2026

Erlotinib hydrochloride (Tarceva) is a targeted therapy approved for advanced non-small-cell lung cancer. It

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Targeted therapies represent a significant advancement in cancer treatment.
  • Epidermal Growth Factor Receptor (EGFR) inhibitors offer a novel approach to managing specific cancers.

Purpose of the Study:

  • To evaluate the efficacy of Erlotinib hydrochloride in patients with advanced non-small-cell lung cancer.
  • To assess the survival benefit of Erlotinib hydrochloride in a pre-treated patient population.

Main Methods:

  • Phase III clinical trials were conducted to assess the drug's effectiveness.
  • Patient cohorts included those who had failed prior chemotherapy regimens.

Main Results:

  • Erlotinib hydrochloride demonstrated an increase in survival in Phase III trials.

Related Experiment Videos

  • This marks a significant milestone for EGFR inhibitors in lung cancer treatment.

    • Conclusions:

    • Erlotinib hydrochloride is an effective treatment option for advanced non-small-cell lung cancer.
    • The drug provides a survival advantage for patients who have undergone prior chemotherapy.